Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative medications work by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these substances increase insulin secretion and suppre

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising approaches for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel class of